Skin Wetting in Burn Survivors
This project will identify the efficacy of whole body skin wetting aimed to attenuate excessive elevations in internal body temperatures during physical activity in well-healed burn survivors. The investigators will conduct a randomized crossover design study. Non-burned control subjects, subjects who experienced burns
| Condition(s) | Burn Injury |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This project will identify the efficacy of whole body skin wetting aimed to attenuate excessive elevations in internal body temperatures during physical activity in well-healed burn survivors. The investigators will conduct a randomized crossover design study. Non-burned control subjects, subjects who experienced burns covering \~20% to 40% of their body surface area, and subject having burns \>40% of their body surface area will be investigated. Subjects will exercise in heated environmental conditions while receiving no cooling or whole body skin wetting. |
| Who can participate | Inclusion Criteria: Non-burn survivors * Healthy male and female subjects * 18-65 years of age. * Free of any underlying medical conditions Exclusion Criteria (non-burned individuals): * Any burn-related injuries resulting in at least one night of hospitalization. * Heart disease or any other chronic medical condition requiring regular medical therapy including cancer, diabetes, and hypertension. * Abnormalities detected on routine screening * Individuals who participate in a structured aerobic exercise training program at moderate to high intensities. * Current smokers, as well as individuals who regularly smoked within the past 3 years. * Body mass index of greater than 30 kg/m\^2. * Pregnant individuals Inclusion Criteria (burn survivors): * Healthy male and female subjects * 18-65 year |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | University of Texas Southwestern Medical Center |
| Locations | Dallas, Texas, United States |
| Start date | 2024-07-31 |
| NCT ID | NCT06529757 |
| Official listing | https://clinicaltrials.gov/study/NCT06529757 |